6-K - GDTC - Equibles

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM6-K

REPORTOF FOREIGN PRIVATE ISSUER

PURSUANTTO RULE 13a-16 OR 15d-16

UNDERTHE SECURITIES EXCHANGE ACT OF 1934

Forthe month of July 2025

CommissionFile Number: 001-41677

CytoMedTHerapeutics Limited

(Translation of registrant’s name into English)

1Commonwealth Lane

#08-22

Singapore149544

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

On May 1, 2025, the Compensation Committee and the Board of Directors of CytoMed Therapeutics Limited (the “Company”) approved the issuance of ordinary shares to the following individuals as compensation for their continued service to the Company:

(i)	11,250<br> ordinary shares to Dr. Lucas Luk Tien Wee, Chief Clinical Officer, subject to a six-month<br> restriction period from the date of issuance;
(ii)	25,781<br> ordinary shares to Ms. Goh Yvonne, Chief Financial Officer, subject to a six-month restriction<br> period from the date of issuance;
(iii)	25,781<br> ordinary shares to Ms. Tan Yoong Ying, Chief Corporate Officer, subject to a six-month restriction<br> period from the date of issuance; and
(iv)	469<br> ordinary shares to Dr. Yew Chak Hua, Independent Director, subject to a six-month restriction<br> period from the date of issuance.

On July 1, 2025, the Company entered into supplemental agreements to the existing appointment agreements with each of the above individuals to formally effect the grant of the respective ordinary shares.

| 2 |

| --- |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited.
Date:<br> July 3, 2025	By:	/s/ Choo Chee Kong
	Name:	Choo<br> Chee Kong
	Title:	Chairman<br> & Director

| 3 |

| --- |